24 assets in Myeloid Sarcoma

Therapeutic assets addressing Myeloid Sarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cytarabine Myeloid Sarcoma	Kura Oncology, Inc.	P3	BB (70)
Mitoxantrone Myeloid Sarcoma	Ruijin Hospital	P3	BB (67)
Daunomycin Myeloid Sarcoma	Kura Oncology, Inc.	P3	BB (66)
Venetoclax Myeloid Sarcoma	Ruijin Hospital	P2	BB (65)
Cyclophosphamide Myeloid Sarcoma	St. Jude Children's Research Hospital	P3	BB (64)
Azacitidine Myeloid Sarcoma	Ruijin Hospital	P2	B (60)
Cladribine Myeloid Sarcoma	University of Washington	P2	B (60)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit Myeloid Sarcoma	St. Jude Children's Research Hospital	P2	CCC (53)
Blinatumomab Myeloid Sarcoma	St. Jude Children's Research Hospital	P2	CCC (53)
Dexrazoxane Myeloid Sarcoma	M.D. Anderson Cancer Center	P2	CCC (53)
Fludarabine Myeloid Sarcoma	St. Jude Children's Research Hospital	P2	CCC (53)
Gemtuzumab Ozogamicin Myeloid Sarcoma	M.D. Anderson Cancer Center	P2	CCC (53)
Hpc, Cord Blood Myeloid Sarcoma	St. Jude Children's Research Hospital	P2	CCC (53)
Idarubicin Myeloid Sarcoma	M.D. Anderson Cancer Center	P2	CCC (53)
Melphalan Myeloid Sarcoma	St. Jude Children's Research Hospital	P2	CCC (53)
Mesna Myeloid Sarcoma	St. Jude Children's Research Hospital	P2	CCC (53)
Rituximab Myeloid Sarcoma	St. Jude Children's Research Hospital	P2	CCC (53)
Sirolimus Myeloid Sarcoma	St. Jude Children's Research Hospital	P2	CCC (53)
Tacrolimus Myeloid Sarcoma	St. Jude Children's Research Hospital	P2	CCC (53)
Thiotepa Myeloid Sarcoma	St. Jude Children's Research Hospital	P2	CCC (53)
Recombinant Human Granulocyte Colony-Stimulating Factor Myeloid Sarcoma	University of Washington	P1/2	CCC (48)
Hpc-A Myeloid Sarcoma	St. Jude Children's Research Hospital	P2	CC (43)
Quizartinib Myeloid Sarcoma	Kura Oncology, Inc.	P1	CC (43)
Ziftomenib Myeloid Sarcoma	Kura Oncology, Inc.	P1	CC (43)